Detemir

ApprovedSmall molecule

Eli Lilly

Detemir is one of 112 small molecule programs targeting Hypoglycemia. It is currently in Approved.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypoglycemiaActive, not recruiting

Type 2 DiabetesActive, not recruiting

ObesityActive, not recruiting

Type 1 DiabetesActive, not recruiting

HypoglycemiaApproved

Active, not recruiting

Type 2 DiabetesPhase 3

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Type 1 DiabetesPreclinical

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Detemir

Eli Lilly

Approved

3 2

Byetta

AstraZeneca

Preclinical

55 3

Jardiance

Boehringer Ingelheim

Preclinical

31 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/AActive, not recruiting

Obesity

NCT01239550

Clinical

Trials by Indication[1]

Type 2 Diabetes3 trials

A Comparison Between Glargine and Detemir Insulin in Type 2 Diabetes

Completed·DDiabetes Care Center·N/A·NCT00457093·35 enrolled

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes (IOOY)

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00494013·442 enrolled

The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT01966978·157 enrolled

Diagnosis1 trial

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis

Unknown status·KKarolinska Institutet·Phase 4·NCT01271517·120 enrolled

Obesity1 trial

Insulin Detemir in Obesity Management

Active, not recruiting·VVanderbilt University·N/A·NCT01239550·240 enrolled

Effectiveness1 trial

Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy

Completed·UUniversity of Colorado, Denver·N/A·NCT01186003·30 enrolled

Hypoglycemia1 trial

Hypoglycemia Counterregulation and Symptom Perception With Insulin Detemir

Terminated·UUniversity Hospital Tuebingen·Phase 4·NCT00490893·12 enrolled

3 more indications

Type 1 Diabetes1 trial

Comparison of a Twice Daily Versus a Three Times Daily Insulin Regimen in Children With Type 1 Diabetes

Completed·UUniversity of Calgary·N/A·NCT00522210·18 enrolled

Open Heart Surgery1 trial

Transitioning Open Heart Surgery Patients From Insulin Infusions to Detemir

Completed·OOhio State University·Phase 4·NCT00717288·82 enrolled

Unspecified4 trials

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Completed·UUniversity of Aarhus·Phase 3·NCT01461616·19 enrolled

Detemir Energy Expenditure Study

Completed·UUniversity of Surrey·Phase 4·NCT00788840·30 enrolled

Endothelial Effects of Basal Insulin: Detemir Versus Glargine

Completed·UUniversity of Padova·Phase 4·NCT00699686·50 enrolled

Show 1 more trial

Hospital In-Patient Insulin Study

Terminated·—·Phase 4·NCT00135070·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Detemir. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Detemir compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Detemir. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Eli Lilly

Detemir

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Type 2 Diabetes3 trials

Diagnosis1 trial

Obesity1 trial

Effectiveness1 trial

Hypoglycemia1 trial

Type 1 Diabetes1 trial

Open Heart Surgery1 trial

Unspecified4 trials

References

Drug Info

Quick Facts

Related News